This document can be used to prepare or evaluate feasibility of ancillary study proposals and paper proposals, but is NOT intended for publication.

Study Case-Control Types

File Name	Data as of	Population	Data collected	One row per	Rows
spec_case_control_types_ctos_inv.dat	3/14/2023	CT+OS	Baseline, Main, Ext1, Ext2	Case/Control type	179,182

Please be careful when using these data. These assignments were created at case/control selection time and often have more to do with the complexities of the case/control selection process and the procedures required to perform the study than analysis. Study designs are often very complex and these assignments may not adequately describe those complexities. You may want to contact the study PI to determine case/control assignments appropriate for analysis.

ID - WHI Participant Common ID

Col 1

N	Missing	Min	Max	Mean	StdDev
179,182	0	100,001	299,999	199,835.711	57,643.647

STUDYID - Study ID

Col 2

Value	Description	N	%
189	Biochemical & anthropometric measures among obese	1,316	0.7
191	Biomarkers & genetic factors rel. to sarcopenia (with as199)	3,072	1.7
195	Candidate pathways in colorectal carcinogenesis	2,376	1.3
206	Selenium and colorectal cancer	1,601	0.9
207	IGF and multiple myeloma	591	0.3
208	Pro and anti-inflammatory cytokines and colorectal cancer	1,340	0.7
214	Prospective cohort in pancreatic cancer (AS146 extension)	627	0.3
238	Biochemical predictors of type 2 diabetes mellitus in women	1,941	1.1
242	DNA repair, telomere length and melanoma	471	0.3
254	Liu/Telomere/diabetes	4,029	2.2
266	EGFR-signaling-network activators/inhibitor & lung ca	2,982	1.7
275	Urinary levels of melatonin and risk of breast cancer	794	0.4
282	Serum markers for multi-stage ovarian cancer screening	1,750	1
284	Obesity/Breast Disease	2,098	1.2
290	Cadmium Exposure and Risk of Breast Cancer	1,508	0.8
292	Advanced Glycation End Products,receptor and Colorectal Ca	1,213	0.7
294	Lung CA & one-carbon metabolis	484	0.3
296	Cohort study of etiology of hepatocellular carcinoma	360	0.2
297	Estrogens, estr. metabolites & androgens/endo & ovarian ca	1,860	1
321	Estrogen DNA adducts: estrogen biomarker and breast cancer	962	0.5
325	Ethnic Differences in 25(OH)D and PTH Levels and CVD	4,812	2.7
327	Vit D/Lung Ca/never smoking	600	0.3
332	AVIIR score in predicting incident CHD	1,400	0.8
346	Serum, vitamin D, and risk of melanoma in WHI-OS	1,359	0.8
362	Glycation/obesity/pancreatic C	1,981	1.1
374	HPV /head and neck cancer	396	0.2
383	VitD/BR and Colorectal Ca	58	0
389	Multiple myeloma/adipo levels	591	0.3
402	Biomarkers and risk of ALS	362	0.2
403	Systemic and breast-cancer specific autoimmunity in the WHI	99	0.1
411	Excess mortality in women with rheumatoid arthritis	325	0.2
422	Cardiovascular biomarkers in WHI Native Americans	588	0.3
425	A Pilot Study of Urinary Bisphenol-A in WHI	90	0.1
455	Colorectal cancer	1,612	0.9
458	Reeves_Phthalate metabolites and BRCA	1,257	0.7
471		214	0.1
476	APOL1, sickle cell, kidney	3,816	2.1
482	Esophageal adenocarcinoma	76	0
523	haptoglobin phenotype/risk of CHD/Stroke	400	0.2
537	Endogenous SERM, cholesterol metabolite, 27HC, fracture	858	0.5
562	Sex steroid hormones; primary liver cancer	361	0.2
584		300	0.2
BA10	Adipokines and risk of obesity-related disease	4,519	2.5
BA11	Physical activity, obesity, inflammation and CHD	1,933	1.1
BA12	HRT, estrogen metabolism and breast cancer or hip fracture	2,861	1.6
BA13	B-cell stimulation markers and non-Hodgkins lymphoma	980	0.5
BA18	Followup studies of genetically determined risk factors	871	0.5
BA20	Arthritis, inflammation, thrombogenesis and CVD/mortality	13,120	7.3
BA21	Understanding the role of sex hormones in colorectal cancer	1,203	0.7
BA22	Predictive modeling for CVD in a multiethnic cohort in women	3,997	2.2
BA25	Leukocyte Telomere Dynamics	3,365	1.9
BA6	Inflamation genes, diet, medication, and cancer	4,086	2.3
BA7	Estradiol/estrogen and CHD, fx, stroke, VTE, cog imp.	3,634	2
BA8	Predictive value of nutrient biomarkers for CHD death	2,443	1.4
BA9	Biochemical antecedents of fracture in minority women	2,264	1.3
M11	NCI - Upper GI cancer GWAS and telomere length	435	0.2
W1	CT 6% Subsample, Clinic CBCs, QC Pools	4,546	2.5
W10	Biological markers of the effect of HT on breast cancer	1,510	0.8
W11	CVD biomarkers - Phase II: strokes after Feb. 2001	622	0.3
W14	CVD biomarkers - Phase I: additional assays	1,792	1
W15	Vit D and colorectal cancer or fractures in CaD trial	3,631	2
W18	HT Hormone Pretest	240	0.1
W2	OS-measurement precision study (OS-MPS)	1,082	0.6
W22	Vitamin D levels in 6% blood subsample of CaD	599	0.3
W24	Vitamin D and breast cancer in CaD trial	2,161	1.2
W27	NPAAS lab work	445	0.2
W39	27-hydroxycholesterol in CVD biomarkers (W-6)	1,163	0.6
W45	Proteomic Colon Cancer Study	200	0.1
W5	Endogenous sex hormones in DM trial	300	0.2
W54	CVD Biomarkers for 2010-2015 (SHARe cohort only)	11,967	6.7
W57	HT Proteomics on B2M and IGFBP4	706	0.4
W58	CVD, diabetes, and renal biomarkers in the EA HT Cohort	10,161	5.7
W6	HT CVD Biomarkers: study of CHD, Stroke and VTE - Phase I	1,794	1
W64	Long Life Study (LLS)	7,452	4.2
W66	Long Life Study-Phase III Biomarkers and GWAS	1,494	0.8
W8	Nutritional biomarkers study (NBS)	543	0.3
W9	Sex hormones and fractures	1,500	0.8
83	Thrombotic, inflammatory and genetic markers for CHD	630	0.4
90	WHI sex hormone and genetic risk factors for hip fracture	800	0.4
97	Ovarian cancer serum markers	838	0.5
105	Carotenoids in age-related eye disease study (CAREDS)	1,989	1.1
110	Sex hormones and CHD	1,275	0.7
121	Hyperinsulinemia and ovarian cancer	445	0.2
126	Stroke risk factors and molecular markers	1,944	1.1
129	Diabetes+IGF-I in colorectal,breast,endometrial caner	2,599	1.5
132	Genetic and biochemical predictors of type 2 diabetes	3,782	2.1
133	Predictors of hypertension in white and black women	1,600	0.9
134	Estrone, HRT, and breast cancer	389	0.2
146	A prospective study of pancreatic cancer pathogenesis	416	0.2
165	Thyroid dysfunction and MI/stroke risk	4,490	2.5
167	Sex hormones and ER+/ER- breast cancer	902	0.5
179	Frailty in WHI: drugs, inflammatory and genetic markers	1,799	1
181	Hip fracture estradiol, cytokines, bone turnover	800	0.4
187	Serum fatty acids and incidence of ischemic stroke in women	1,935	1.1

CCNAME - Case Control Type Name

Col 3

A short name describing the case control type.

N	Missing
179,182	0

CASEFLG - Case Flag

Col 4

Y=Case, N=Control, N/A=Study was not a case/control design.

Usage Notes:

Note that in some studies the same participant may act as both a case and a control (e.g. studies looking at multiple outcomes).

Value	Description	N	%
N	No - Control	60,293	33.6
NA	Not Applicable	45,776	25.5
Y	Yes - Case	73,113	40.8